What the published results consistently show

Across the published studies available, the most consistent finding is a roughly 30-point rise on the IKDC Subjective Knee Score — patients typically enter treatment scoring around 48, indicating moderate-to-severe activity limitation, and reach approximately 80 at the three-year mark. That trajectory has been reproduced in both a 2016 prospective multicentre study and Simeonov's 2024 cohort of 17 knee patients (mean age 31), where statistically significant IKDC and Lysholm improvements were recorded at 3, 6, and 12 months (p<0.05).

The 30-point gain matters because it clears the accepted minimum clinically important difference of 16.7 IKDC points — the threshold below which a change on the scale would be unlikely to translate into anything a patient notices in daily life. Crossing it suggests the improvement is felt, not merely measurable.

Pooled published figures place the responder rate at 70–85% in appropriately selected patients, with a reoperation rate of 3–8%. Where follow-up data are available, meaningful relief has lasted 2–5 years — a longer horizon than symptom-management options such as hyaluronic acid or corticosteroid injections, which typically require repeat courses.

One recovery pattern is worth noting for anyone planning a return to activity: the bulk of functional gain appears to consolidate within the first six months. In Simeonov's cohort, no statistically significant additional change was detected between the 6- and 12-month readings, suggesting the improvement curve flattens well within the first year rather than continuing to climb.

The treatment itself is delivered as an ultrasound-guided outpatient injectable collagen scaffold — the gel polymerises in situ within 3–5 minutes of injection, meaning no surgical admission is required.

How improvement is measured and what the scores mean

Two outcome measures appear repeatedly in ChondroFiller studies, and understanding what they actually capture helps put the published numbers in context.

The IKDC Subjective Knee Score is a 100-point patient-reported questionnaire: zero reflects complete functional inability; 100 reflects no limitation whatsoever. A score of 48 — typical at baseline in these cohorts — corresponds to significant restriction: difficulty with stairs, limited walking distance, and an inability to sustain sport or physical activity. A score of 80 generally reflects comfortable everyday use, including walking longer distances, cycling, and light-to-moderate recreational activity without significant pain.

MOCART (Magnetic Resonance Observation of Cartilage Repair Tissue) is an MRI-based system that scores how completely a defect has filled and how well repair tissue integrates with the surrounding native cartilage, running from 0 to 100. One-year scores of 70–87 indicate that scaffold integration and defect filling are substantially complete on imaging.

Structural repair on MRI and patient-reported symptom relief are distinct measurements — a well-integrated scaffold does not automatically guarantee pain-free function. In the reported cohorts, however, MOCART scores in this range have accompanied the functional gains patients report, providing biological corroboration rather than proof. Asking a specialist which measures the clinic tracks — and over what follow-up period — makes the results easier to compare meaningfully with the published literature.

Evidence in joints beyond the knee

The knee evidence does not stand alone. Mazek's 2021 prospective hip cohort (n=26, acetabular lesions larger than 2 cm²) followed patients for 3–5 years and found 17 of 21 evaluable patients achieved good-to-excellent results. The caveat is direct: those with Tönnis grade 2 or 3 degeneration — a radiographic scale that measures hip joint wear, where grade 2–3 indicates moderate-to-severe osteoarthritic change — had consistently poor outcomes, suggesting the scaffold cannot compensate for a joint that has lost its broader structural integrity.

In the wrist, a 2025 prospective study by Matta et al. (n=59 distal radius fracture patients, 25 treated with ChondroFiller) demonstrated significantly better cartilage quality at follow-up arthroscopy: a median Outerbridge score of 1.5 versus 3.0 in controls (p=0.006), and ICRS grade 1 versus 3 (p=0.002). Notably, fibrous tissue only formed where the defect was overfilled; flush applications were complication-free.

Across all three joint types, the same pattern holds: focal defects against a background of reasonably preserved joint health show the clearest benefit. Advanced osteoarthritis appears to be a consistent relative contraindication regardless of the joint involved. Patients should therefore ask their specialist to evaluate the condition of the joint as a whole — not only the size of the focal defect — before any suitability decision is reached.

Why the scaffold works — and what the early recovery data signals

Unlike cell-based cartilage therapies, ChondroFiller contains no transplanted donor cells. 'Acellular' simply means the scaffold arrives empty — its job is to act as a structural framework that invites the patient's own progenitor cells, drawn from the synovium and subchondral bone, to migrate in and begin the repair process. This mechanism is known as acellular matrix-induced chondrogenesis.

A 2025 ex vivo osteochondral model provided direct biological confirmation: the ChondroFiller group showed a 2.4-fold increase in DNA content by day 14, indicating active cell migration into the scaffold. Adding mesenchymal stem cells enhanced collagen and glycosaminoglycan production further, though this remains a laboratory finding rather than a clinical protocol.

A separate 2024 biomechanical in-vitro study introduced a practical recovery consideration. ChondroFiller in its early post-injection state could not reduce load-related damage to opposing cartilage surfaces compared with an untreated defect, a finding the authors attributed to the gel's initial mechanical instability before integration is established. The implication is straightforward: published science supports a structured, phased return to weight-bearing rather than immediate full activity following injection.

Patients should ask their specialist for a clear rehabilitation protocol before proceeding — specifically, what activity restrictions apply in the first weeks and at what point graduated loading can begin.

Limitations and gaps the evidence does not yet answer

Before committing to any treatment, patients deserve a clear account of what the evidence does not yet establish — and for ChondroFiller, several gaps are specific enough to name.

Study scale and design

The pivotal clinical trial published in 2016 enrolled 23 patients: 13 received ChondroFiller, 10 were assigned to microfracture. Within the microfracture arm, 6 of the 10 patients declined to undergo surgery once randomised, so the head-to-head comparison the trial was designed to deliver never materialised in any meaningful sense. The ChondroFiller arm did show statistically significant IKDC improvements at 3, 6, and 12 months, but those results cannot be weighed against a functioning comparator arm.

Beyond that trial, the remaining published record consists primarily of small European single-centre cohort studies, some involving manufacturer engagement. No large independent multicentre randomised controlled trial has been completed. A US orthopaedic commentary has noted directly that no published evidence currently demonstrates ChondroFiller outperforms existing procedures such as microfracture in a properly controlled setting — a fair observation that patients and clinicians alike should factor in.

Regulatory status

ChondroFiller holds a CE mark (Gel: 2012; Liquid: 2013) but has not received FDA approval and is not available for clinical use in the United States. In the UK, it sits outside NHS provision and is not covered by most private medical insurance, meaning it is accessed exclusively through self-funded private pathways. These are factual points about access and regulatory status, not a clinical judgement on the treatment itself — but they are relevant to any patient weighing their options.

Component evidence versus whole-protocol evidence

The NanoACi protocol — which combines ChondroFiller with autologous cartilage micrografts and platelet-rich fibrin, delivered without arthroscopy — rests on two distinct layers of evidence. Each component has published support in its own right, and ChondroFiller alone has been used in over 20,000 implantations across more than a decade. What does not yet exist is a randomised trial validating the three-part combination as a unified protocol; prospective outcomes are currently being gathered through the NanoACi 100 study. Patients considering this pathway should ask their specialist to be explicit about which evidence applies to the individual components and which, if any, applies to the combined regimen.

None of this makes these questions unanswerable — it makes them the right ones to ask. A specialist who can discuss study scale, comparator design, and the component-versus-protocol distinction clearly is one worth consulting.

Finding a specialist and the questions worth asking

The evidence is clearest for a specific patient profile: a focal, contained defect — typically under 3 cm² — in a joint without significant background osteoarthritis. Within that profile, the published functional and structural outcomes tell a reasonably consistent story across knee, hip, and wrist cohorts. Outside it, results deteriorate markedly, as the hip data on Tönnis grade 2–3 patients demonstrates directly. Whether a given patient fits that profile is precisely what a consultation must establish.

Four questions are worth raising directly:

• Which outcome measures does the clinic track, and over what follow-up period — and how do their reported results compare with published figures?
• Is the proposed approach ChondroFiller alone or a combination protocol, and what evidence supports the specific combination versus its individual components?
• What does the rehabilitation protocol require, and when does graduated weight-bearing begin?
• Has the joint as a whole been assessed to rule out advanced degeneration as a relative contraindication — not only the focal defect in isolation?

A specialist who engages clearly with all four is the right kind of specialist to consult.

Search MSK lists specialists across the UK who offer ChondroFiller and injectable scaffold treatments — filter by region and specialty to find one suited to your situation.